• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session

    12/14/22 2:04:00 PM ET
    $ARQQ
    $ASPU
    $AVDL
    $BHG
    Computer Software: Prepackaged Software
    Technology
    Other Consumer Services
    Consumer Discretionary
    Get the next $ARQQ alert in real time by email

    Gainers

    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
    • Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares jumped 140% to $0.6041 after the company entered into a definitive merger agreement with GRI Bio.
    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) gained 52% to $0.2175. Panbela received EMA opinion on orphan designation for Ivospemin in combination with Gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
    • Immix Biopharma, Inc. (NASDAQ:IMMX) jumped 46% to $2.1695 after the company announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 with 85% ORR and 71% CR/sCR at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial.
    • Senti Biosciences, Inc. (NASDAQ:SNTI) rose 45% to $2.09 after dipping more than 21% on Tuesday.
    • Avidity Biosciences, Inc. (NASDAQ:RNA) shares climbed 44.3% to $15.84 after the company announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever successful targeted delivery of RNA into muscle.
    • BIMI International Medical, Inc. (NASDAQ:BIMI) gained 28.1% to $2.6649. BIMI reported entry into a material definitive agreement for the acquisition of Wuzhou Qiangsheng Hospital Co., Ltd., Suzhou Eurasia Hospital Co., Ltd. and Yunan Yuxi Minkang Hospital Co., Ltd.
    • Wave Life Sciences Ltd. (NASDAQ:WVE) gained 21.1% to $5.80. SVB Leerink maintained WAVE Life Sciences with a Market Perform and raised the price target from $2 to $7.
    • Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares gained 21.4% to $31.38 after the company announced results from the Phase 1 clinical trial evaluating KT-474 in patients with HS and AD and Sanofi's decision to advance KT-474 into Phase 2 clinical trials.
    • Aspen Group, Inc. (NASDAQ:ASPU) gained 17.4% to $0.41 after reporting strong quarterly sales.
    • REV Group, Inc. (NYSE:REVG) jumped 17.2% to $15.57 as the company reported a fourth-quarter FY22 sales growth of 5.7% year-over-year to $623.6 million, beating the consensus of $595 million.
    • Nuvve Holding Corp. (NASDAQ:NVVE) gained 16.9% to $0.7477.
    • Meiwu Technology Company Limited (NASDAQ:WNW) jumped 16.3% to $2.14.
    • United Insurance Holdings Corp. (NASDAQ:UIHC) jumped 16.2% to $0.5578.
    • Dyne Therapeutics, Inc. (NYSE:DYN) jumped 14.7% to $14.00.
    • Sio Gene Therapies Inc. (NASDAQ:SIOX) gained 14.7% to $0.3537.
    • Otonomy, Inc. (NASDAQ:OTIC) jumped 14.4% to $0.1399.
    • Harmonic Inc. (NASDAQ:HLIT) gained 12.9% to $14.86
    • Happiness Development Group Limited (NASDAQ:HAPP) rose 12.9% to $3.9973after surging over 10% on Tuesday.
    • Carvana Co. (NYSE:CVNA) gained 12.8% to $5.45.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) jumped 12.4% to $1.90.
    • Harrow Health, Inc. (NASDAQ:HROW) surged 11.9% to $12.43. Harrow Health entered a binding agreement to acquire the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from Novartis.
    • Mullen Automotive, Inc. (NASDAQ:MULN) jumped 10% to $0.2354. Mullen Automotive partnered with Loop Global to deploy EV charging solutions, including public DC fast charging network and residential offerings.
    • QualTek Services Inc. (NASDAQ:QTEK) gained 9.3% to $0.5463.
    • Cytokinetics, Incorporated (NASDAQ:CYTK) jumped 7.6% to $41.27. The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8-3 against the approval of Cytokinetics heart failure drug, omecamtiv mecarbil.
    • Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) gained 6.3% to $2.02. Processa Pharmaceuticals said PCS12852 successfully improves the clinical symptoms associated with gastroparesis in Phase 2A trial.

     

    Losers

    • Drive Shack Inc. (NYSE:DS) fell 55.3% to $0.2126. The company announced its intention to voluntarily delist from the NYSE and to deregister its common stock.
    • ZyVersa Therapeutics Inc (NASDAQ:ZVSA) dipped 36.5% to $4.76.
    • Netcapital Inc. (NASDAQ:NCPL) shares dipped 33.3% to $1.47 after the company announced pricing of a public offering.
    • OpGen, Inc. (NASDAQ:OPGN) fell 29.8% to $0.1621. OpGen shares jumped around 85% on Tuesday after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
    • Puhui Wealth Investment Management Co., Ltd. (NASDAQ:PHCF) fell 25.7% to $2.95.
    • Kaspien Holdings Inc. (NASDAQ:KSPN) fell 24.2% to $0.7490 after the company reported a wider Q3 loss.
    • Versus Systems Inc. (NASDAQ:VS) declined 23.1% to $0.5998.
    • SeqLL Inc. (NASDAQ:SQL) dropped 21.7% to $0.3789.
    • Vincerx Pharma, Inc. (NASDAQ:VINC) declined 21.7% to $0.83.
    • Avadel Pharmaceuticals plc (NASDAQ:AVDL) fell 20.9% to $6.52.
    • Getaround, Inc. (NYSE:GETR) fell 20.4% to $1.09.
    • Bit Brother Limited (NASDAQ:BTB) dropped 20% to $0.4238 after the company announced a 1-for-15 reverse share split.
    • Oriental Culture Holding LTD (NASDAQ:OCG) declined 18.8% to $0.71.
    • Yumanity Therapeutics, Inc. (NASDAQ:YMTX) fell 16.8% to $1.6886. Yumanity Therapeutics recently declared a special dividend in connection with the proposed asset sale to Janssen and merger with Kineta.
    • Baudax Bio, Inc. (NASDAQ:BXRX) fell 16.6% to $2.5925.
    • Summit Therapeutics Inc. (NASDAQ:SMMT) fell 16.4% to $3.2691.
    • Bright Health Group, Inc. (NYSE:BHG) dropped 16% to $0.6137. Goldman Sachs, on Tuesday, downgraded Bright Health from Neutral to Sell.
    • Arqit Quantum Inc. (NASDAQ:ARQQ) fell 14.7% to $5.33 after the company reported FY22 results and filed for a mixed shelf of up to $100 million..
    • Charter Communications, Inc. (NASDAQ:CHTR) fell 13.3% to $340.65 after it communicated an increase in 2023 capital expenditures at its analyst day held on Tuesday.
    • Rubicon Technology, Inc. (NASDAQ:RBCN) shares fell 13.1% to $1.5814. Rubicon Technology announced voluntary delisting from the Nasdaq.
    • Nexalin Technology, Inc. (NASDAQ:NXL) fell 11.1% to $1.7250.
    • Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) dropped 11% to $12.32.
    • LAVA Therapeutics N.V. (NASDAQ:LVTX) fell 9.4% to $4.20. LAVA Therapeutics announced updated data from the Phase 1/2a clinical trial of LAVA-051 at the 64th American Society of Hematology Annual Meeting and Exposition.
    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) fell 7.1% to $0.1327 after gaining around 53% on Tuesday. Panbela Therapeutics, last month, posted a Q3 loss of $0.21 per share.

    Also check this out Bitcoin Tops $18,000; GMX, Dogecoin Among Top Losers.

    Get the next $ARQQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARQQ
    $ASPU
    $AVDL
    $BHG

    CompanyDatePrice TargetRatingAnalyst
    Atrium Therapeutics Inc.
    $RNA
    3/11/2026$25.00Overweight
    Wells Fargo
    Immix Biopharma Inc.
    $IMMX
    3/9/2026$23.00Mkt Outperform
    Citizens
    Immix Biopharma Inc.
    $IMMX
    2/9/2026$14.00Outperform
    Mizuho
    Wave Life Sciences Ltd.
    $WVE
    2/5/2026$38.00Buy
    BofA Securities
    Kymera Therapeutics Inc.
    $KYMR
    1/28/2026$133.00Overweight
    Barclays
    Cytokinetics Incorporated
    $CYTK
    1/28/2026$87.00Overweight
    Barclays
    Charter Communications Inc.
    $CHTR
    1/13/2026$180.00Equal Weight → Underweight
    Wells Fargo
    Kymera Therapeutics Inc.
    $KYMR
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $ARQQ
    $ASPU
    $AVDL
    $BHG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Jankovic Walter converted options into 1,457 shares and covered exercise/tax liability with 513 shares, increasing direct ownership by 0.67% to 141,539 units (SEC Form 4)

    4 - HARMONIC INC. (0000851310) (Issuer)

    3/13/26 6:26:06 PM ET
    $HLIT
    Radio And Television Broadcasting And Communications Equipment
    Technology

    President and CEO Ben-Natan Nimrod converted options into 20,032 shares, increasing direct ownership by 3% to 655,525 units (SEC Form 4)

    4 - HARMONIC INC. (0000851310) (Issuer)

    3/13/26 6:24:37 PM ET
    $HLIT
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Director Posner Brian S bought $38,700 worth of shares (2,000 units at $19.35), increasing direct ownership by 17% to 13,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/13/26 4:46:19 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQQ
    $ASPU
    $AVDL
    $BHG
    SEC Filings

    View All

    SEC Form DEFA14A filed by Carvana Co.

    DEFA14A - CARVANA CO. (0001690820) (Filer)

    3/13/26 9:05:16 AM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    SEC Form PRE 14A filed by Carvana Co.

    PRE 14A - CARVANA CO. (0001690820) (Filer)

    3/13/26 9:01:00 AM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    SEC Form DEFA14A filed by Charter Communications Inc.

    DEFA14A - CHARTER COMMUNICATIONS, INC. /MO/ (0001091667) (Filer)

    3/12/26 4:11:49 PM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    $ARQQ
    $ASPU
    $AVDL
    $BHG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Atrium Therapeutics with a new price target

    Wells Fargo initiated coverage of Atrium Therapeutics with a rating of Overweight and set a new price target of $25.00

    3/11/26 8:36:38 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Immix Biopharma with a new price target

    Citizens initiated coverage of Immix Biopharma with a rating of Mkt Outperform and set a new price target of $23.00

    3/9/26 9:07:22 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Immix Biopharma with a new price target

    Mizuho initiated coverage of Immix Biopharma with a rating of Outperform and set a new price target of $14.00

    2/9/26 7:01:42 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQQ
    $ASPU
    $AVDL
    $BHG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Charter to Participate in NSR/BCG Global Connectivity Leaders Conference

    STAMFORD, Conn., March 13, 2026 /PRNewswire/ -- Charter Communications, Inc. (NASDAQ:CHTR) (along with its subsidiaries, "Charter") today announced that Jessica Fischer, Chief Financial Officer, will participate in the NSR and BCG Global Connectivity Leaders Conference in New York, New York on Thursday, March 26, 2026. Ms. Fischer's remarks are scheduled to begin at 11:00 a.m. ET. A live webcast of the event can be accessed on Charter's investor relations website, ir.charter.com. Following the live broadcast, the webcast will be archived at ir.charter.com.About CharterCharter Co

    3/13/26 3:30:00 PM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    Carvana Board of Directors Approves 5 for 1 Forward Stock Split

    Carvana (NYSE:CVNA), the industry pioneer for buying and selling cars online, today announced that its Board of Directors approved a 5 for 1 split of its common stock. The split is designed to ensure that earning and buying whole shares of Carvana stock is within reach for all of its team members. "This is the first split in Carvana's history, and we believe it achieves the important goal of keeping our stock accessible to all of our team members," said Mark Jenkins, Chief Financial Officer of Carvana. "This decision follows significant stock appreciation as Carvana reached new all-time records for units and profitability while continuing to lead the industry in growth in 2025." Carvana

    3/13/26 9:05:00 AM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Harmonic Redefines the Economics of Video Playout with New Spectrum X Plus Media Server

    Advanced Media Server Delivers Double the Channel Density at Half the Cost per Channel of Previous GenerationsSAN JOSE, Calif., March 12, 2026 /PRNewswire/ -- Harmonic (NASDAQ:HLIT) today announced Spectrum™ X Plus, the newest generation of its Spectrum X media server, offering double the channel density of previous generations. Spectrum X Plus dramatically simplifies video ingest and playout functions for broadcasters and content owners, significantly lowering the total cost per channel for broadcast delivery. Spectrum X Plus strengthens Harmonic's leadership in playout-to-delivery solutions by enabling broadcasters to deploy high performance playout infrastructure on premises, in the cloud

    3/12/26 8:00:00 AM ET
    $HLIT
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ARQQ
    $ASPU
    $AVDL
    $BHG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posner Brian S bought $38,700 worth of shares (2,000 units at $19.35), increasing direct ownership by 17% to 13,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/13/26 4:46:19 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Posner Brian S bought $45,180 worth of shares (3,000 units at $15.06), increasing direct ownership by 35% to 11,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/10/26 5:33:53 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Krall David bought $499,044 worth of shares (47,528 units at $10.50), increasing direct ownership by 27% to 223,125 units (SEC Form 4)

    4 - HARMONIC INC. (0000851310) (Issuer)

    12/15/25 7:50:36 PM ET
    $HLIT
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ARQQ
    $ASPU
    $AVDL
    $BHG
    Leadership Updates

    Live Leadership Updates

    View All

    CHARTER COMMUNICATIONS NAMES FRONTIER CEO NICK JEFFERY CHIEF OPERATING OFFICER

    STAMFORD, Conn., Feb. 25, 2026 /PRNewswire/ -- Charter Communications, Inc. (NASDAQ:CHTR) today announced the appointment of Nick Jeffery as its Chief Operating Officer. Jeffery will lead Marketing and Sales, Field Operations, and Customer Operations across Spectrum's residential and business Seamless Connectivity and Entertainment services. Based in Stamford, Jeffery will begin on September 1, 2026. In his new role as Chief Operating Officer, Jeffery will work closely as part of Charter's senior leadership team to build on the Company's assets, enhance its service reputation an

    2/25/26 8:30:00 AM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

    BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry. "Carlo's appointment comes at a pivotal moment for Sparrow as we are looking ahead to pivotal trials of clofutriben for type 2 diabetes and seeking to expand development into other cardiometabolic indications," said Robert Jacks, Sparrow President and Chief Executive Officer. "Carlo is respected globally for

    2/2/26 8:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQQ
    $ASPU
    $AVDL
    $BHG
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET. A webcast replay will be available on the Events page of the Investors section of the Company's website (sentibio.com). Interested parties may access the live video webcast here. About Senti Bio Senti Bio is a biotechnolog

    3/3/26 9:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

    Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Cash and cash equivalents of $72.9 million as of December 31, 2025Full-year 2026 revenue guidance of $350 million to $365 million, including $133 million to $153 million in the first half of

    3/2/26 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass Planning underway to initiate Phase 2a multidose portion of WVE-007 INLIGHT clinical trial for obesity in individuals with higher BMI and comorbidities in 1H 2026, as well as additional trials of WVE-007 as an incretin add-on and as post-incretin maintenance in 2026 Advancing regulatory engagement on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing) for AATD with feedback anticipated mid-2026; RestorAATion-2 clinical trial fully enrolled through 60

    2/26/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQQ
    $ASPU
    $AVDL
    $BHG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Arqit Quantum Inc.

    SC 13D/A - Arqit Quantum Inc. (0001859690) (Subject)

    12/13/24 8:03:28 PM ET
    $ARQQ
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Arqit Quantum Inc.

    SC 13D/A - Arqit Quantum Inc. (0001859690) (Subject)

    12/10/24 8:05:26 PM ET
    $ARQQ
    Computer Software: Prepackaged Software
    Technology

    $ARQQ
    $ASPU
    $AVDL
    $BHG
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care